专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013037484A2 ANTI-APLHABETATCR ANTIBODY 审中-公开
标题翻译：抗APLHABETATCR抗体
公开(公告)号：WO2013037484A2
公开(公告)日：2013-03-21
申请号：PCT/EP2012/003819
申请日：2012-09-12
申请人： GENZYME CORPORATION , SNELL, Daniel , MENRAD, Andreas , LACORCIA, Gina , SHANKARA, Shrinivas , QIU, Huawei , PAN, Clark
发明人： SNELL, Daniel , MENRAD, Andreas , LACORCIA, Gina , SHANKARA, Shrinivas , QIU, Huawei , PAN, Clark
IPC分类号： C07K16/28
CPC分类号： C07K16/2809 , C07K16/2893 , C07K2317/24 , C07K2317/31 , C07K2317/71 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
摘要翻译：本发明涉及包含鼠抗体BMA031的CDR的人源化单克隆抗体，其与apTCR.CD3复合物结合并具有改善的生物学性质。

2. 发明申请

WO2013095905A1 THYROID STIMULATING HORMONE COMPOSITIONS 审中-公开
标题翻译：甲状腺刺激激素组合物
公开(公告)号：WO2013095905A1
公开(公告)日：2013-06-27
申请号：PCT/US2012/067705
申请日：2012-12-04
申请人： GENZYME CORPORATION , PAN, Clark , PARK, Sunghae , QIU, Huawei
发明人： PAN, Clark , PARK, Sunghae , QIU, Huawei
IPC分类号： A61K47/48 , A61P35/00
CPC分类号： A61K47/48215 , A61K38/00 , A61K38/24 , A61K47/60
摘要： Described herein are compositions of Thyroid Stimulating Hormone (TSH), wherein at least one polyalkylene glycol polymer is attached to a carbohydrate site of the TSH. Also described are compositions of mutated Thyroid Stimulating Hormone (TSH) and at least one polyalkylene glycol polymer, wherein the mutated TSH comprises a TSH in which one or more amino acid residues has been substituted with cysteine residue, and the polyalkylene glycol polymer is attached to the mutated TSH at the site of the substituted cysteine residue. Pharmaceutical compositions comprising these TSH compositions and method of treating a thyroid condition in a patient in need thereof, by administering to the patient an effective amount of the pharmaceutical compositions are also described.
摘要翻译：本文描述的是甲状腺刺激激素（TSH）的组合物，其中至少一种聚亚烷基二醇聚合物连接到TSH的碳水化合物位点。还描述了突变的甲状腺刺激激素（TSH）和至少一种聚亚烷基二醇聚合物的组合物，其中突变的TSH包含其中一个或多个氨基酸残基被半胱氨酸残基取代的TSH，并且聚亚烷基二醇聚合物附着于在取代的半胱氨酸残基的位点处的突变的TSH。还描述了包含这些TSH组合物的药物组合物和在有需要的患者中治疗甲状腺疾病的方法，通过向患者施用有效量的药物组合物。

3. 发明申请

WO2004111198A2 MODIFIED HUMAN ACID SPHINGOMYELINASE HAVING INCREASED ACTIVITY, AND METHODS FOR MAKING THE SAME 审中-公开
标题翻译：具有增加活性的改良人乳球蛋白酶及其制备方法
公开(公告)号：WO2004111198A2
公开(公告)日：2004-12-23
申请号：PCT/US2004/018515
申请日：2004-06-10
申请人： GENZYME CORPORATION , VAN PATTEN, Scott, M. , KAREY, Kenneth, P. , QIU, Huawei
发明人： VAN PATTEN, Scott, M. , KAREY, Kenneth, P. , QIU, Huawei
IPC分类号： C12N
CPC分类号： C12N9/16
摘要： Deficiencies in the enzymatic activity of acid sphingomyelinase (ASM) result in Niemann-Pick disease. A variety of modifications which eliminate the activity of the free thiol on the C-terminal cysteine residue of ASM all result in substantially increased specific activity of the enzyme. Methods used to alter the activity of this residue include site-directed mutagenesis to delete or alter the residue, enzymatic degradation of the ASM to remove the residue, copper-promoted dimerization of ASM (via the terminal cysteine residues) and chemical modification of the free thiol group on this residue.
摘要翻译：酸性鞘磷脂酶（ASM）的酶活性不足导致尼曼 - 皮克病。消除ASM的C-末端半胱氨酸残基上的游离巯基活性的各种修饰都导致酶的比活性显着提高。用于改变该残基活性的方法包括定点诱变以删除或改变残基，ASM酶促降解以除去残留物，铜促进的ASM二聚化（通过末端半胱氨酸残基）和化学修饰游离该残基上的硫醇基。

4. 发明申请

WO2008157367A1 FUSION PROTEINS CONTAINING TWO TGF-BETA BINDING DOMAINS OF TGF-BETA TYPE II RECEPTOR 审中-公开
标题翻译：含有TGF-β2受体的两个TGF-β结合域的融合蛋白
公开(公告)号：WO2008157367A1
公开(公告)日：2008-12-24
申请号：PCT/US2008/066941
申请日：2008-06-13
申请人： GENZYME CORPORATION , QIU, Huawei , LEDBETTER, Steven, R. , KYOSTIO-MOORE, Sirkka
发明人： QIU, Huawei , LEDBETTER, Steven, R. , KYOSTIO-MOORE, Sirkka
IPC分类号： C12N15/62 , C07K14/71 , C12N15/12 , A61K38/17
CPC分类号： C07K14/71 , A61K38/00 , C07K2319/32
摘要： The disclosure provides fusion proteins that contain two TGF-β binding domains of TGF-β type Il receptor joined to each other by a linker. For example, the C terminus of the first TGF-β binding domain is joined by a short peptide linker (e.g., a 9-glycine linker) to the N terminus of the second TGF-β binding domain. Despite the proximity of the C terminus of the first domain to N terminus of the second domain, such a fusion protein effectively neutralizes TGF-β, in some cases, similarly to anti-TGF-β antibodies.
摘要翻译：本公开提供了融合蛋白，其包含通过连接体彼此连接的TGF-βII型受体的两个TGF-β结合结构域。例如，第一TGF-β结合结构域的C末端通过短肽接头（例如，9-甘氨酸接头）连接到第二TGF-β结合结构域的N末端。尽管第一结构域的C末端邻近第二结构域的N末端，但是在某些情况下，这种融合蛋白有效中和TGF-β，与抗TGF-β抗体类似。

5. 发明申请

WO2018136698A2 BONE-TARGETING ANTIBODIES 审中-公开
公开(公告)号：WO2018136698A2
公开(公告)日：2018-07-26
申请号：PCT/US2018/014350
申请日：2018-01-19
申请人： GENZYME CORPORATION
发明人： QIU, Huawei , PARK, Sunghae , STEFANO, James
IPC分类号： C07K16/22
摘要： Provided are recombinant and chemically-conjugated antibodies and fragments thereof modified with one or more poly-aspartate (poly-D) peptides {e.g., a D10 sequence) to improve localization of the antibodies or fragments to bone. Methods of making and using of these antibodies and fragments also are disclosed.

6. 发明申请

WO2014164709A2 ENGINEERED ANTI-TGF-BETA ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS 审中-公开
标题翻译：工程抗TGF-β抗体和抗结合片段
公开(公告)号：WO2014164709A2
公开(公告)日：2014-10-09
申请号：PCT/US2014/023274
申请日：2014-03-11
申请人： GENZYME CORPORATION
发明人： WEI, Ronnie , MOULIN, Aaron , MATHIEU, Magali , PAN, Clark , PARK, Sunghae , QIU, Huawei
IPC分类号： A61K39/395
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/567 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： Antibodies or antigen-binding fragments thereof are engineered to bind Transforming Growth Factor-β (TGFβ). TGFβ-isoform selective antibodies or antigen-binding fragments thereof may selectively bind human TGFβ1, compared to human TGFβ2 and human TGFβ3, or may selectively bind human TGFβ3, compared to human TGFβ1 and human TGFβ2. The design of the antibodies or antigen-binding fragments thereof is facilitated by a co-crystal structure of a recombinant Fab fragment of GC1008 bound to TGFβ2 and by another co-crystal structure of the scFv version of GC1008 bound to TGFβ1.
摘要翻译：抗体或其抗原结合片段被工程化以结合转化生长因子-β（TGFβ）。与人TGFβ2和人TGFβ3相比，TGFβ同种型选择性抗体或其抗原结合片段可以选择性结合人TGFβ1，或者可以选择性结合人TGFβ3。抗体或其抗原结合片段的设计通过与TGFβ2结合的GC1008的重组Fab结构和与TGFβ1结合的scFv形式的GC1008的另一种共晶体结构来促进。

7. 发明申请

WO2014151644A2 ANTI-CD52 ANTIBODIES 审中-公开
标题翻译：抗CD52抗体
公开(公告)号：WO2014151644A2
公开(公告)日：2014-09-25
申请号：PCT/US2014/026159
申请日：2014-03-13
申请人： GENZYME CORPORATION
发明人： QIU, Huawei , WEI, Ronnie, Rong , PAN, Clark, Qun , SENDAK, Rebecca
IPC分类号： C07K16/24
CPC分类号： C07K16/2893 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/734 , C07K2317/92 , C07K2317/94
摘要： Anti-human CD52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments. The antibodies and fragments can be used in therapeutic applications to treat, for example, autoimmune diseases, cancer, and graft rejection.
摘要翻译：提供抗人CD52抗体及其抗原结合片段。还提供了用于制备抗体和片段的分离的核酸，重组载体和宿主细胞。抗体和片段可用于治疗应用，例如治疗自身免疫性疾病，癌症和移植排斥反应。

8. 发明申请

WO2014043361A1 FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION 审中-公开
标题翻译：含有改性糖苷化和还原效应功能的含FC多糖
公开(公告)号：WO2014043361A1
公开(公告)日：2014-03-20
申请号：PCT/US2013/059481
申请日：2013-09-12
申请人： GENZYME CORPORATION
发明人： PAN, Clark , QIU, Huawei
IPC分类号： C07K16/28
CPC分类号： C07K16/2809 , C07K16/2851 , C07K16/2893 , C07K16/32 , C07K16/40 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2317/92
摘要： Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
摘要翻译：提供了结合多肽（例如抗体）及其药物偶联物，其包含具有改变的糖基化谱和降低的效应子功能的Fc结构域。在特定实施方案中，Fc结构域包括：根据EU编号在氨基酸位置298处的天冬酰胺残基; 以及根据EU编号在氨基酸位置300处的丝氨酸或苏氨酸残基。还提供了编码抗原结合多肽的核酸，用于产生这种抗原结合多肽的重组表达载体和宿主细胞。还提供了使用本文公开的抗原结合多肽治疗疾病的方法。

9. 发明申请

WO2022040560A1 FGFR3 ANTIBODIES AND METHODS OF USE 审中-公开
公开(公告)号：WO2022040560A1
公开(公告)日：2022-02-24
申请号：PCT/US2021/046958
申请日：2021-08-20
申请人： GENZYME CORPORATION
发明人： SABBAGH, Yves , CHEN, Yangde , BRONDYK, William , QIU, Huawei , PARK, Sunghae , WEI, Ronnie , QIU, Yu , ZHOU, Yanfeng , LEMOINE, Cendrine , CHO, HyunSuk
IPC分类号： A61P19/08 , C07K16/28
摘要： Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

10. 发明申请

WO2021016571A2 METHODS OF TREATING ANTIBODY-MEDIATED DISORDERS WITH FCRN ANTAGONISTS 审中-公开
公开(公告)号：WO2021016571A2
公开(公告)日：2021-01-28
申请号：PCT/US2020/043533
申请日：2020-07-24
申请人： GENZYME CORPORATION
发明人： MACKNESS, Brian , QIU, Huawei
IPC分类号： C07K16/18 , A61P37/06 , A61K2039/505 , A61K39/39533 , A61K51/10 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/70 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present disclosure provides methods of treating an antibody-mediated disorder (e.g., an autoimmune disease) using an FcRn antagonist, e.g., a binding polypeptide (e.g., an antibody and/or an immunoadhesin), comprising a modified Fc domain. The present disclosure also provides methods of enhancing diagnostic imaging using an FcRn antagonist disclosed herein. The present disclosure further provides methods of reducing exposure of normal tissue to a radiolabeled antibody during diagnostic imaging using an FcRn antagonist disclosed herein. Methods comprising administering to a subject a therapeutically effective amount of an FcRn antagonist disclosed herein are also provided.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式